Adoption of new line(s) of business

Ref. No: HSCL / Stock-Ex/2026-27/44 Date: 15/07/2026 E-mail: monika@himadri.com Ref: Listing Code: 500184 Ref: Listing Code: HSCL BSE Limited National Stock Exchange of India Ltd Department of Corporate Services Exchange Plaza, C-1, Block-G P. J. Towers, 25th Floor, Bandra Kurla Complex, Dalal Street, Bandra (E) Mumbai- 400 001 Mumbai- 400 051 Sub: Outcome of Board Meeting held on 15 July 2026 - Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, We refer to our letter dated 08 July 2026 intimating about the meeting of the Board of Directors ("Board") of Himadri Speciality Chemical Ltd (“Company”/ “Himadri”) scheduled to be held on 15 July 2026, inter-alia to approve and take on record the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended 30 June 2026. Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform you that the Board of the Company at its’ meeting held today i.e. on 15 July 2026, inter-alia has considered and approved the following: 1. Unaudited Financial Results (Consolidated & Standalone) for the quarter ended 30 June 2026 is enclosed as ‘Annexure-I’. We are enclosing herewith the following pursuant to Regulation 30 and Regulation 33 read with the applicable provisions of Schedule III and Part A of Schedule IV of the SEBI Listing Regulations and SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: i) Unaudited Financial Results (Consolidated and Standalone) for the quarter ended 30 June 2026. ii) The Limited Review Report of the Statutory Auditors of the Company, M/s Singhi & Co, Chartered Accountants on the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended 30 June 2026. 2. Capex of Rs 128 Crores for expanding the capacity to manufacture Anthraquinone and Carbazole from 2600 MTPA to 5300 MTPA. This has reference to our earlier announcement dated 13 January 2025 wherein the Board approved Capex of Rs. 120 Crores for setting up facility to manufacture high-value specialty products, Anthraquinone and Carbazole for 2600 MTPA. At its meeting held today, the Board has approved an additional capex of Rs. 128 Crores to enhance the project's capacity from 2600 MTPA to 5300 MTPA. This capex will be funded primarily through internal accruals. The proposed capex will not result in any change in the Company's existing overall production capacity. The project will be implemented in two phases: o Phase 1 – Capacity of 2600 MTPA to be commissioned by Q2FY27. o Phase 2 – Balance capacity of 2700 MTPA, expected to be commissioned by Q2FY28. 3. Capex of Rs. 70 Crores for setting up India’s First manufacturing facility of Carbon Nano Tubes (CNT) in West Bengal with In-house developed technology. Aligned with Company’s vision to expand into high-value products, we have successfully developed in-house technology to manufacture Carbon Nano Tubes (CNT) through relentless R&D efforts, marking another milestone in our innovation journey. The Board at its meeting held today has approved a capex for setting up manufacturing facility in West Bengal for production of CNT, with an annual production capacity of 200 MT at an estimated project cost of Rs. 70 Crores, to be funded through internal accruals. This facility will be India’s First CNT manufacturing facility with in-house developed technology and is expected to be commissioned by Q4FY27. The manufacturing of CNT will position Himadri among a select group of few global manufacturers serving this high-growth market. CNT is widely used in industries such as: Electric vehicles (EVs) – lithium-ion battery conductive additives, Electronics – semiconductors, conductive films, sensors, Composites – lightweight, high-strength materials for aerospace and automotive, Energy – batteries, supercapacitors, fuel cells, Industrial coatings and plastics – improving electrical conductivity and mechanical strength. This strategic move marks a significant step towards reducing import dependency and aligns with Company’s commitment towards the Government of India's vision of an Atmanirbhar Bharat. Disclosures required under Regulation 30 read with Schedule III of the SEBI Listing Regulations read along with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as ‘Annexure-II’. 4. Capex of Rs. 170 Crores for manufacturing of Super Speciality Carbon Black. The Board has approved a capex for manufacturing Super Speciality Carbon Black (SSCB) with production capacity of 6,000 MTPA with an estimated project cost of Rs 170 crores to be funded primarily through internal accruals. However, the overall capacity of Carbon Black of 2,50,000 MTPA (out of which 1,20,000 MTPA is commodity grade and 1,30,000 MTPA is Speciality Carbon Black) remains unchanged as 6000 MTPA will be converted from our existing carbon black stream. This facility will enable the Company to produce superior & different morphology & high purity Carbon Black at its existing carbon black facility at Mahistikry and is expected to be commissioned by Q4FY28. This Super Speciality Carbon Black will deliver significantly higher value realization across niche applications such as Engineering plastics & conductive applications, Fiber Industry growth & premiumisation, EV & energy storage ecosystem expansion, etc., thereby strengthening the Company’s leadership in the highly specialized market. The Meeting of the Board of Directors commenced at 11:30 a.m. (IST) and concluded at 3:25 p.m. (IST) The above information will be made available on the Company’s website at www.himadri.com We request you to kindly take on record the same. Thanking you, Yours faithfully, For Himadri Speciality Chemical Ltd Monika Saraswat (Company Secretary & Compliance Officer) ACS: 29322 Annexure-I Sing/ii� Co. 16S1a,r at Bose Road Kolkata0-276{0,I0 n dia) T+ 91(0)336-020401/90 1/02 Chartered Accountants Ek olkata@singhico.com www.singhico.com IndepeAnuddeisntR toe rv'iReewp oornUt n audCiotnesdo lFiidnaatRneecdsi uaollfHt ism aSdpreaicl iiCthye miLmciiaetldfo rth e quaretnedrJe udn 3e02 ,0 2p6u rsutaoRn etg ul3a3to ifSo EnB( IL isOtbilnigg aantDdii osnc lRoesquurier eRmegeuntlitaosn)s , 201a5sa, m ended ThBeo aorfDd i rectors HimaSdpreic iCahleimtiLyci amli ted 1.Weh avree vietwhaeecd c ompaunnyaiundsgit taetde omfce onnts olfiidnaatrneecdlsi tuaoslfH imaSdpreic iality Chemical Limi(theedr eirneaffettroaer stre h d"e P arCeonmtp aannyid"t s)su bsid(itPahareri Ceeonsmt p aanniydt ssu bsidiaries together refetroar ste hd"e G rofuoptr"h )qe u aretnedrJe udn 3e02 ,0 2t6o gewtihtnehor t tehse r(ehoenra efitrnee rf etroar se' dt he statembeenistnu'gb) m,i btytt hePeda reCnotm papnuyr stuoat nhrtee quiroefRm eegnutl 3a3ot fiS oEnB( IL isOtbilnigg ations anDdi sclRoesquurier eRmeegnutlsa2)t0 i1ao5san mse,n d(e"dtR heeg ulaatnihdoa bnse" e)in n itbiyua slf eoidrd entification purpose. 2.Thsitsa tewmhehini ctts,h r ee sponosfti hbPeia lriCetonymt p aMnayn'asg eamneadnp tp robvyte hdPe a rCeonmpta nByo'asr d ofD irecitnto hremsie,re thienlogdn J uly 1h5a,bs e 2ep0nr2 e6p airnae cdc orwdiatnthchr eee cogannimdte iaosnu rement princliadpioldwe insnt hIen dAicacno uSnttainn3dg4a " rIdn tFeirniamRn ecpioartl(i "nIgAn"S3d 4 "p)r,e scurnidbSeeerdc tion 13o3ft hCeo mpaAnci2te0,s1 r 3e awdi trhe lervualinestss tuheedur ned aenrod t haecrc oupnrtiinncggi epnleerasac lcleyp ted in IOnudrri eas.p onistsioi b sisalru ieetp yoo nrt thS et atebmaesnoetnod u rre view. 3.Wec onduocutrree dv ioeftw h set ateimnae cncto rdwainttchhSe et andoanR redv iEenwg age(mSeR2nE4t)1 " 0R evoifew InteFriinma ncial PeIrnffoobrrymmt aehItdeni doenp eAnuddeinottfto hrEe n tity," speci1f4i3(e 1do0 f)tu hneder Section CompaAnci2te0,s1 T3hi.ss t anrdeaqrudti hrwaeetsp laannp de rftohrreme vtioeow bt amiond eraastseu ra [Showing first 8,000 characters — download PDF for full document]